WGU D116 ADVANCED PHARMACOLOGY OBJECTIVE
ASSESSMENT Comprehensive Resource To Help You Ace
2026-2027 Includes Frequently Tested Questions With
ELABORATED 100% Correct COMPLETE SOLUTIONS
Guaranteed Pass First Attempt!!
Current Update!!
1. A patient has taken a narcotic analgesic for chronic pain for several months. At
a follow-up appointment, the provider notes that the patient has been taking
more than the prescribed dosage. The patient has normal vital signs, is awake
and alert, and reports mild pain. What does the provider suspect is responsible
for the patient's response?
Correct Answer: A. This patient has developed pharmacodynamic tolerance,
which has increased the minimal effective concentration (MEC) needed for
analgesic effect.
Feedback: Pharmacodynamic tolerance results when a patient takes a drug over a
long period of time. Adaptive processes occur in response to chronic receptor
occupation. The result is that the body requires increased drug, or an increased
MEC, to achieve the same effect. Tachyphylaxis is a form of tolerance that can be
defined as a reduction in drug responsiveness brought on by repeated dosing over
a short time. Induced synthesis of hepatic enzymes increases metabolism of a
drug, but it does not increase the MEC.
2. Which patient ethnic ancestry creates a risk factor that may result in minimal
beneficial response to tamoxifen therapy?
Correct Answer: French
,Feedback: Between 8% and 10% of women of European ancestry have a gene
variant that prevents the effective metabolism of tamoxifen that negatively affects
the medication’s therapeutic effect.
3. Before initiating cetuximab therapy, the provider will order epidermal growth
factor receptor (EGFR) testing for the patient having which condition?
Correct Answer: A. Colorectal cancer
Feedback: Cetuximab is used mainly for metastatic colorectal cancer. The
medication works only against tumors that express EGRF; all other tumors are
unresponsive. This makes testing in advance of treatment required.
4. When prescribing drugs with a narrow therapeutic index, what intervention
does the provider take to decrease risk to the patient?
Correct Answer: D. Monitor the patient’s plasma drug levels at regular intervals.
Feedback: A drug with a narrow therapeutic range or index is more difficult to
administer safely, because the difference between the minimum effective
concentration and the toxic concentration is small. Patients taking these
medications must have their plasma drug levels monitored closely to ensure that
they are getting an effective dose that is not toxic. Administering medications at
longer intervals risks increased periods of subtherapeutic levels. Drugs that have a
narrow therapeutic range may be given by any route; intravenous administration
is not preferable and in most cases will not be feasible. Medication regimen
adherence is necessary; however, due to individual variation, for drugs with a
narrow therapeutic range, what is an effective dose for one patient may be a
lethal dose for another. For this reason, monitoring drug levels remains the
primary method for decreasing risk.
5. A patient reports that Brand X tablets work faster than Brand Y tablets of the
same amount of the same drug. Which statement informs the prescriber's
response when explaining this phenomenon to the patient?
, Correct Answer: B. Inactive ingredients used in composition can result in differing
rates of dissolution, which can alter the drug’s onset of action.
Feedback: Even if two brands of a drug are chemically equivalent (i.e., they have
identical amounts of the same chemical compound), they can have different
effects in the body if they differ in bioavailability. Tablets made by different
manufacturers contain different binders and fillers, which disintegrate and
dissolve at different rates and affect the bioavailability of the drug.
6. A patient receiving intravenous gentamicin has a toxic serum drug level. The
prescriber confirms that the dosing is correct. Which possible cause of this
situation will the provider explore?
Correct Answer: B. Whether patient is taking a medication that binds to serum
albumin
Feedback: Gentamicin binds to albumin, but only weakly, and in the presence of
another drug that binds to albumin, it can rise to toxic levels in blood serum. A
loading dose increases the initial amount of a drug and is used to bring drug levels
to the desired plateau more quickly. A drug that is not completely dissolved
carries a risk of causing embolism but this addresses a different concern. A drug
given at a frequency longer than the drug half-life will likely be at subtherapeutic
levels and not at toxic levels.
7. A patient takes a drug that is metabolized by CYP3A4 isoenzymes. If a CYP3A4
inducing drug is prescribed, what drug adjustment may be necessary to maintain
a therapeutic level of CYP3A4 substrate?
Correct Answer: B. Increase dosage of the CYP3A4 substrate.
Feedback: A drug that acts as an inducing agent for an enzyme system increases
the metabolism of drugs metabolized by that enzyme system, thereby lowering
the level of those drugs in the body and requiring higher doses to maintain drug
effectiveness. Although decreasing the dosage of the drug that induces
metabolism may seem reasonable at first glance, this may decrease the
ASSESSMENT Comprehensive Resource To Help You Ace
2026-2027 Includes Frequently Tested Questions With
ELABORATED 100% Correct COMPLETE SOLUTIONS
Guaranteed Pass First Attempt!!
Current Update!!
1. A patient has taken a narcotic analgesic for chronic pain for several months. At
a follow-up appointment, the provider notes that the patient has been taking
more than the prescribed dosage. The patient has normal vital signs, is awake
and alert, and reports mild pain. What does the provider suspect is responsible
for the patient's response?
Correct Answer: A. This patient has developed pharmacodynamic tolerance,
which has increased the minimal effective concentration (MEC) needed for
analgesic effect.
Feedback: Pharmacodynamic tolerance results when a patient takes a drug over a
long period of time. Adaptive processes occur in response to chronic receptor
occupation. The result is that the body requires increased drug, or an increased
MEC, to achieve the same effect. Tachyphylaxis is a form of tolerance that can be
defined as a reduction in drug responsiveness brought on by repeated dosing over
a short time. Induced synthesis of hepatic enzymes increases metabolism of a
drug, but it does not increase the MEC.
2. Which patient ethnic ancestry creates a risk factor that may result in minimal
beneficial response to tamoxifen therapy?
Correct Answer: French
,Feedback: Between 8% and 10% of women of European ancestry have a gene
variant that prevents the effective metabolism of tamoxifen that negatively affects
the medication’s therapeutic effect.
3. Before initiating cetuximab therapy, the provider will order epidermal growth
factor receptor (EGFR) testing for the patient having which condition?
Correct Answer: A. Colorectal cancer
Feedback: Cetuximab is used mainly for metastatic colorectal cancer. The
medication works only against tumors that express EGRF; all other tumors are
unresponsive. This makes testing in advance of treatment required.
4. When prescribing drugs with a narrow therapeutic index, what intervention
does the provider take to decrease risk to the patient?
Correct Answer: D. Monitor the patient’s plasma drug levels at regular intervals.
Feedback: A drug with a narrow therapeutic range or index is more difficult to
administer safely, because the difference between the minimum effective
concentration and the toxic concentration is small. Patients taking these
medications must have their plasma drug levels monitored closely to ensure that
they are getting an effective dose that is not toxic. Administering medications at
longer intervals risks increased periods of subtherapeutic levels. Drugs that have a
narrow therapeutic range may be given by any route; intravenous administration
is not preferable and in most cases will not be feasible. Medication regimen
adherence is necessary; however, due to individual variation, for drugs with a
narrow therapeutic range, what is an effective dose for one patient may be a
lethal dose for another. For this reason, monitoring drug levels remains the
primary method for decreasing risk.
5. A patient reports that Brand X tablets work faster than Brand Y tablets of the
same amount of the same drug. Which statement informs the prescriber's
response when explaining this phenomenon to the patient?
, Correct Answer: B. Inactive ingredients used in composition can result in differing
rates of dissolution, which can alter the drug’s onset of action.
Feedback: Even if two brands of a drug are chemically equivalent (i.e., they have
identical amounts of the same chemical compound), they can have different
effects in the body if they differ in bioavailability. Tablets made by different
manufacturers contain different binders and fillers, which disintegrate and
dissolve at different rates and affect the bioavailability of the drug.
6. A patient receiving intravenous gentamicin has a toxic serum drug level. The
prescriber confirms that the dosing is correct. Which possible cause of this
situation will the provider explore?
Correct Answer: B. Whether patient is taking a medication that binds to serum
albumin
Feedback: Gentamicin binds to albumin, but only weakly, and in the presence of
another drug that binds to albumin, it can rise to toxic levels in blood serum. A
loading dose increases the initial amount of a drug and is used to bring drug levels
to the desired plateau more quickly. A drug that is not completely dissolved
carries a risk of causing embolism but this addresses a different concern. A drug
given at a frequency longer than the drug half-life will likely be at subtherapeutic
levels and not at toxic levels.
7. A patient takes a drug that is metabolized by CYP3A4 isoenzymes. If a CYP3A4
inducing drug is prescribed, what drug adjustment may be necessary to maintain
a therapeutic level of CYP3A4 substrate?
Correct Answer: B. Increase dosage of the CYP3A4 substrate.
Feedback: A drug that acts as an inducing agent for an enzyme system increases
the metabolism of drugs metabolized by that enzyme system, thereby lowering
the level of those drugs in the body and requiring higher doses to maintain drug
effectiveness. Although decreasing the dosage of the drug that induces
metabolism may seem reasonable at first glance, this may decrease the
